Pharmacy Website

FACULTY PROFILE

 

 Arash Hatefi , Ph.D.

Department of Pharmaceutics
William Levine Hall, Rm 222
160 Frelinghuysen Road, Piscataway, NJ, 08854

Phone: 848-445-6366

Email:ahatefi@pharmacy.rutgers.edu


 
Opening Position: Postdoctoral Fellow, please see here:
http://www.postdocjobs.com/jobs/jobdetail.php?jobid=4014681
 
 
Research interests

• Design and development of advanced multifunctional and targeted systems for nucleic acid delivery

   (Nanomedicine)

• Stem cell engineering for cancer therapy

• Recombinant production of difficult-to-make peptides/proteins.

• Cancer Immunotherapy

 
Education
 
1998 – 2002 Ph.D. in Pharmaceutical Sciences
Department of Pharmaceutical Sciences, University of Alberta, Canada
 
2003 – 2006 Postdoctoral Fellow (Recombinant Vector Engineering, Cancer Gene Therapy)
Center for Nanomedicine and Cellular Delivery, University of Maryland, Baltimore, USA
 
Funding
2014-2016     NIH/NIBIB (R21EB016792)
2012-2013     Rutgers University Faculty Research Grant (#281663)
2010-2015     American Society for Pharmacology and Experimental Therapeutics (SURF Program)
2009-2013     Department of Defense Prostate Cancer Program New Investigator Award (PC081055)
2007-2008     Department of Defense Breast Cancer Program Concept Award (BC062929)
2006-2007     American Cancer Society Institutional Research Grant (IRG-77-003-26)
 
 
Selected Peer Reviewed Journal Publications
 
32.     B.A. Khaw, K.S. Gada, V. Patil, R. Panwar, S. Mandapati, A. Hatefi, S. Majewski, A. Weisenberger A. Bispecific antibody complex pre-targeting and targeted delivery of polymer drug conjugates for imaging and therapy in dual human mammary cancer xenografts : Targeted polymer drug conjugates for cancer diagnosis and therapy. Eur J Nucl Med Mol Imaging, 2014 (In press)
 
31.     Y. Wang, L. Zhang, S. Guo, A. Hatefi, L. Huang, Incorporation of histone derived recombinant protein for enhanced disassembly of core-membrane structured liposomal nanoparticles for efficient siRNA delivery. J Control Release 172(1):179-189 (2013)
 
30.     F.S. Nouri, X. Wang, M. Dorrani, Z. Karjoo, A. Hatefi, A Recombinant Biopolymeric Platform for Reliable Evaluation of the Activity of pH-Responsive Amphiphile Fusogenic Peptides. Biomacromolecules 14:2033-2040 (2013)
 
29.      H. Parhiz, M. Hashemi, A. Hatefi, W.T. Shier, S.A. Farzad, M. Ramezani, Arginine-Rich Hydrophobic Polyethylenimine; Potent Agent with Simple Components for Nucleic Acid Delivery. Int J Biol Macromol 60:18-27 (2013)
 
28.      Z. Karjoo, H.O. McCarthy, P. Patel, F.S. Nouri, A. Hatefi, Systematic Engineering of Uniform and Highly Efficient Targeted-Shielded Viral-Mimetic Nanoparticles. Small 9(16):2774-83 (2013)
 
27.     T. Minko, A. Hatefi, Preface-tenth international nanomedicine and drug delivery symposium (NanoDDS'12). J Control Release 171(3):259-60 (2013) 
 
26.     F. Soltani, M. Sankian, A. Hatefi, M. Ramezani, Development of a novel histone H1-based recombinant fusion peptide for targeted non-viral gene delivery. Int J Pharm 441(1-2):307-15 (2013)
 
25.     H. Parhiz, M. Hashemi, A. Hatefi , W.T. Shier, S.A.Farzad, M. Ramezani, Molecular weight-dependent genetic information transfer with disulfide-linked polyethylenimine-based nonviral vectors. J Biomater Appl (1):112-24 (2013)
 
24.    F. Sadeghian, S. Hosseinkhani, A. Alizadeh, A. Hatefi, Design, engineering and preparation of a multi-domain fusion vector for gene delivery. Int J Pharm 427(2):393-9 (2012)

23.    K. S. Gada, V. Patil, R. Panwar, A. Hatefi, and B. Khaw. Bispecific Antibody Complex Pre-targeted Delivery of Polymer–Drug Conjugates for  Cancer Therapy. Drug Deliv and Transl Res 2:65–76 (2012)
 
22.    B. F. Canine, Y. Wang, W. Ouyang, and A. Hatefi. Development of Targeted Recombinant Polymers that can deliver siRNA to the Cytoplasm and Plasmid DNA to the Cell Nucleus. J Control Release 405(1-2):196-202 (2011)

21.    H.O. McCarthy, A.V. Zholobenko, Y. Wang, B. Canine, T. Robson, D.G. Hirst, A. Hatefi. Evaluation of a Multi-Functional Nanocarrier for Targeted Breast Cancer iNOS Gene Therapy. Int J Pharm 405(1-2):196-202 (2011)

20.    M. Hashemi, B.H. Parhiz, A. Hatefi, M. Ramezani. Modified polyethyleneimine with histidine-lysine short peptides as gene carrier. Cancer Gene Therapy 1:12-19 (2011)

19.    Y. Wang, B.F. Canine, A. Hatefi, HSV-TK/GCV Cancer Suicide Gene Therapy by a Designed Recombinant Multifunctional Vector. Nanomedicine 7 (2):193-200 (2011)
 
18.    H. Ghandehari, A. Hatefi, Advances in recombinant polymers for delivery of bioactive agents. Adv Drug Delivery Rev, 62 (15):1403 (2010)

17.    B.F. Canine, A. Hatefi, Development of cationic recombinant polymers for gene therapy research, Adv Drug Delivery Rev, 62 (15):1524-9 (2010)

16.    H.O. McCarthy, Y. Wang, S.S. Mangipudi, and A. Hatefi, Advances with the use of bio-inspired vectors towards creation of artificial viruses. Expert Opin Drug Deliv 7 (4) (2010) 1-16.

15.     B.F. Canine, Y. Wang, A. Hatefi, Biosynthesis and characterization of a novel genetically engineered polymer for targeted gene transfer to cancer cells. J Control Release 138 (3) (2009) 188-196.   
   
14.    S.S. Mangipudi, B.F. Canine, Y. Wang, A. Hatefi, Development of a genetically engineered biomimetic vector for targeted gene transfer to breast cancer cells. Mol Pharm 6 (4) (2009) 1100–1109.

13.     A. Hatefi and B. Canine, Perspectives in vector development for systemic cancer gene therapy. Gene Ther Mol Biol 13 (2009) 15-19.

12.    Y. Wang, S.S. Mangipudi, B.F. Canine, A. Hatefi, A designer biomimetic vector with a chimeric architecture for targeted gene transfer. J Control Release 137 (2009) 46-53.   

11.     A. Dehshahri, R.K. Oskuee, W.T. Shier, A. Hatefi, and M. Ramezani, Gene transfer efficiency of high primary amine content, hydrophobic, alkyl-oligoamine derivatives of polyethylenimine. Biomaterials 30 (25) (2009) 4187-94.

10.     A. Hatefi and H. Ghandehari, Recombinant Polymers: Promise for Gene Therapy. Controlled Release Society Newsletter 26 (2) (2009)16-18.

9.     B.F. Canine, Y. Wang, A. Hatefi, Evaluation of the effect of vector architecture on DNA condensation and gene transfer efficiency. J Control Release 129 (2008) 117-123.

8.    A. Hatefi, J. Cappello, H. Ghandehari, Adenoviral gene delivery to solid tumors by recombinant silk-elastinlike protein polymers. Pharm Res 24(4) (2007) 773-779.

7.    A. Hatefi, Z. Megeed, H. Ghandehari, Recombinant polymer-protein fusion: a promising approach towards efficient and targeted gene delivery. J Gene Med 8(4) (2006) 468-476.

6.    M. Haider, A. Hatefi, H. Ghandehari, Recombinant polymers for cancer gene therapy: a minireview. J Control Release 109(1-3) (2005) 108-119.

5.    A. Hatefi, D. Knight, B. Amsden, A biodegradable injectable thermoplastic for localized camptothecin delivery. J Pharm Sci 93(5) (2004) 1195-1204.

4.    B. Amsden, A. Hatefi, D. Knight, E. Bravo-Grimaldo, Development of biodegradable injectable thermoplastic oligomers. Biomacromolecules 5(2) (2004) 637-642.

3.    A. Hatefi, B. Amsden, Biodegradable injectable in situ forming drug delivery systems. J Control Release 80(1-3) (2002) 9-28.

2.    A. Hatefi, B. Amsden, Camptothecin delivery methods. Pharm Res 19(10) (2002) 1389-1399.

1.    M.R. Tehrani and A. Hatefi. Characterization and evaluation of enteric-coated controlled release tablet formulations of diclofenac sodium. Acta Pharmaceut (1996) 46: 285-294.

 
Book Chapter
Karjoo, Z.; Ganapathy, V.; Hatefi, A., Gene Directed Enzyme Prodrug Cancer Therapy. In Gene Therapy of Cancer, Lattime, E. C.; Gerson, S. L., Eds. Elsevier Inc.: 2013, pages 77-91
 
 
Patents
2007       H. Ghandehari, A. Hatefi and Z. Megeed. Recombinant Protein Polymer Vectors for Systemic Gene Delivery. US Patent Number 20070098702.
2014       A. Hatefi, Low-Immunogenic and Efficient Recombinant Fusion Vectors And Methods of Use Thereof. Provisional Patent Application Number 5702US01
 
 
Teaching
Genetically Engineered Drug Delivery Systems (Graduate level course)
Advanced Pharmaceutics (Graduate level course)
Introduction to Pharmaceutics (Pharm.D. level course)

Membership in Professional Organizations
Since 1999       American Association of Pharmaceutical Scientists (AAPS)
Since 2001       Controlled Release Society (CRS)
Since 2002       Canadian Society for Pharmaceutical Scientists (CSPS)
Since 2004       American Society of Gene and Cell Therapy  (ASGCT)
Since 2007       American Society for Pharmacology and Experimental Therapeutics (ASPET)
Since 2007       American Association of Cancer Research  (AACR)